169 related articles for article (PubMed ID: 26999660)
1. Effects of combination PPARγ agonist and angiotensin receptor blocker on glomerulosclerosis.
Matsushita K; Yang HC; Mysore MM; Zhong J; Shyr Y; Ma LJ; Fogo AB
Lab Invest; 2016 Jun; 96(6):602-9. PubMed ID: 26999660
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis.
Naito T; Ma LJ; Yang H; Zuo Y; Tang Y; Han JY; Kon V; Fogo AB
Am J Physiol Renal Physiol; 2010 Mar; 298(3):F683-91. PubMed ID: 20042458
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone, a PPARγ agonist, provides comparable protection to angiotensin converting enzyme inhibitor ramipril against adriamycin nephropathy in rat.
Ochodnicky P; Mesarosova L; Cernecka H; Klimas J; Krenek P; Goris M; van Dokkum RP; Henning RH; Kyselovic J
Eur J Pharmacol; 2014 May; 730():51-60. PubMed ID: 24582928
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis.
Yang HC; Ma LJ; Ma J; Fogo AB
Kidney Int; 2006 May; 69(10):1756-64. PubMed ID: 16598202
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats.
Ma LJ; Marcantoni C; Linton MF; Fazio S; Fogo AB
Kidney Int; 2001 May; 59(5):1899-910. PubMed ID: 11318962
[TBL] [Abstract][Full Text] [Related]
6. Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1.
Ma LJ; Nakamura S; Aldigier JC; Rossini M; Yang H; Liang X; Nakamura I; Marcantoni C; Fogo AB
J Am Soc Nephrol; 2005 Apr; 16(4):966-76. PubMed ID: 15728787
[TBL] [Abstract][Full Text] [Related]
7. Combined therapy of cilazapril and losartan has no additive effects in ameliorating adriamycin-induced glomerulopathy.
Kim HJ; Ryu JH; Han SW; Park IK; Paik SS; Park MH; Paik DJ; Chung HS; Kim SW; Lee JU
Nephron Physiol; 2004; 97(4):p58-65. PubMed ID: 15331931
[TBL] [Abstract][Full Text] [Related]
8. Role of intrarenal angiotensin system activation, oxidative stress, inflammation, and impaired nuclear factor-erythroid-2-related factor 2 activity in the progression of focal glomerulosclerosis.
Kim HJ; Sato T; Rodríguez-Iturbe B; Vaziri ND
J Pharmacol Exp Ther; 2011 Jun; 337(3):583-90. PubMed ID: 21357516
[TBL] [Abstract][Full Text] [Related]
9. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.
Zoja C; Corna D; Gagliardini E; Conti S; Arnaboldi L; Benigni A; Remuzzi G
Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975
[TBL] [Abstract][Full Text] [Related]
10. The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves nitric oxide availability, renin-angiotensin system and aberrant redox regulation in the kidney of pre-hypertensive rats.
Kvandova M; Barancik M; Balis P; Puzserova A; Majzunova M; Dovinova I
J Physiol Pharmacol; 2018 Apr; 69(2):. PubMed ID: 29980143
[TBL] [Abstract][Full Text] [Related]
11. Losartan and pioglitazone ameliorate nephropathy in experimental metabolic syndrome rats.
Kong X; Zhang DY; Wu HB; Li FX
Biol Pharm Bull; 2011; 34(5):693-9. PubMed ID: 21532159
[TBL] [Abstract][Full Text] [Related]
12. AT-1 receptor blockade prevents proteinuria, renal failure, hyperlipidemia, and glomerulosclerosis in the Imai rat.
Rodríguez-Iturbe B; Sato T; Quiroz Y; Vaziri ND
Kidney Int; 2004 Aug; 66(2):668-75. PubMed ID: 15253721
[TBL] [Abstract][Full Text] [Related]
13. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.
Brown NJ; Nakamura S; Ma L; Nakamura I; Donnert E; Freeman M; Vaughan DE; Fogo AB
Kidney Int; 2000 Sep; 58(3):1219-27. PubMed ID: 10972684
[TBL] [Abstract][Full Text] [Related]
14. Podocyte-Related Mechanisms Underlying Survival Benefit of Long-Term Angiotensin Receptor Blocker.
Zhu X; Gao D; Albertazzi V; Zhong J; Ma LJ; Du L; Shyr Y; Kon V; Yang HC; Fogo AB
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682697
[TBL] [Abstract][Full Text] [Related]
15. Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype.
Yamamoto S; Zhong J; Yancey PG; Zuo Y; Linton MF; Fazio S; Yang H; Narita I; Kon V
Atherosclerosis; 2015 Sep; 242(1):56-64. PubMed ID: 26184694
[TBL] [Abstract][Full Text] [Related]
16. Additive effect of PPAR-γ agonist and ARB in treatment of experimental IgA nephropathy.
Lai KN; Chan LY; Guo H; Tang SC; Leung JC
Pediatr Nephrol; 2011 Feb; 26(2):257-66. PubMed ID: 21125406
[TBL] [Abstract][Full Text] [Related]
17. Selonsertib Enhances Kidney Protection Beyond Standard of Care in a Hypertensive, Secondary Glomerulosclerosis CKD Model.
Badal SS; Al Tuhaifi T; Yu YF; Lopez D; Plato CT; Joly K; Breckenridge DG; Yang HC; Liles JT; Fogo AB
Kidney360; 2022 Jul; 3(7):1169-1182. PubMed ID: 35919527
[TBL] [Abstract][Full Text] [Related]
18. Late angiotensin II receptor blockade in progressive rat mesangioproliferative glomerulonephritis: new insights into mechanisms.
Villa L; Boor P; Konieczny A; Kunter U; van Roeyen CR; Denecke B; Gan L; Neusser MA; Cohen CD; ; Eitner F; Scholl T; Ostendorf T; Floege J
J Pathol; 2013 Apr; 229(5):672-84. PubMed ID: 23192593
[TBL] [Abstract][Full Text] [Related]
19. Coinhibition of immune and renin-angiotensin systems reduces the pace of glomerulosclerosis in the rat remnant kidney.
Hamar P; Peti-Peterdi J; Rázga Z; Kovács G; Heemann U; Rosivall L
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S234-8. PubMed ID: 9892170
[TBL] [Abstract][Full Text] [Related]
20. Reduction of renal lipid content and proteinuria by a PPAR-γ agonist in a rat model of angiotensin II-induced hypertension.
Sakamoto A; Hongo M; Saito K; Nagai R; Ishizaka N
Eur J Pharmacol; 2012 May; 682(1-3):131-6. PubMed ID: 22387860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
